Henriksen MB, Hansen TF, Jensen LH, et al. A collection of multiregistry data on patients at high risk of lung cancer-a Danish retrospective cohort study of nearly 40,000 patients. Transl Lung Cancer Res. 2023;12(12):2392-2411. doi:10.21037/tlcr-23-495

Ebrahimi, A., Henriksen, M.B.H., Brasen, C.L. et al. Identification of patients’ smoking status using an explainable AI approach: a Danish electronic health records case studyBMC Med Res Methodol 24, 114 (2024).

Issa MA, Clementsen PF, Laursen CB, Vilmann P, Christiansen IS, Crombag L, Bodtger U. Using the Endoscope for Endobronchial Ultrasound in the Esophagus. J Vis Exp. 2023 Nov 21;(201). doi: 10.3791/65741. PMID: 38078614.

Issa, M. A., Clementsen, P. F., Laursen, C. B., Christiansen, I. S., Crombag, L., Vilmann, P., & Bodtger, U. (2024). Added value of EUS-B-FNA to bronchoscopy and EBUS-TBNA in diagnosing and staging of lung cancerEuropean Clinical Respiratory Journal11(1).

AG Ording, TD Christensen, F Skjøth, S Noble, AA Højen, AL Mørkved, TB Larsen, RH Petersen, P Meldgaard, E Jakobsen, M Søgaard. Risk of venous thromboembolism in patients with stage III and IV non-small cell lung cancer: Nationwide descriptive cohort study. Accepted Clinical Lung Cancer 2024.

AG Ording, F Skjøth, LØ Poulsen, WM Szejniuk, E Jakobsen, TD Christensen, S Noble, TF Overvad. Time toxicity of systemic anticancer therapy for metastatic lung cancer in routine clinical practice: descriptive nationwide cohort study. Submitted Journal of Clinical Oncology 2024.

Gouliaev, A., Ali, F., Jakobsen, E., Dalton, S. O., Hilberg, O., Rasmussen, T. R., & Christensen, N. L. (2024). The Danish lung cancer registry: A nationwide validation study. Lung Cancer, 107527.

Jørgensen, C. U., Løkke, A. Hjorth, P., Pisinger, C., Farver-Vestergaard, I., (2024) Barriers to implementation of smoking cessation support among healthcare professionals in the secondary healthcre sector. A qualitative and quantitative evaluation. Tob. Prev. Cessation 2024;10(February):12

Farver-Vestergaard I; Hjorth P; Pisinger C; Larsen P V; Løkke A A survey exploring the practices of smoking cessation support among hospital-based healthcare providers. MC Health Services Research (2023) 23:645

Olloni, A., et al., Does Coronary artery calcium score have an impact on overall survival for locallyadvanced non-small cell lung cancer treated with definitive radiotherapy. Radiotherapy and Oncology.

Borg A, Wen S W C et a.l. Methylated Circulating Tumor DNA in Blood as a Tool for Diagnosing Lung Cancer: A Systematic Review and Meta-Analysis, Cancers, 2023. 

A Olloni, C Brink, EL Lorenzen, SS Jeppesen, L Hofmann, C Kristiansen, MM Knap(, DS Møller, L Nygård, GF Persson, RS Thing, HM Sand, A Diederichsen, T Schytte. Does Coronary artery calcium score have an impact on overall survival for locally advanced non-small cell lung cancer treated with definitive radiotherapy DOI: 10.1016/j.radonc.2023.109719

A Olloni, EL Lorenzen, S Jeppesen et al.  An open source auto-segmentation algorithm for delineating heart and substructures – Development and validation within a multicenter lung cancer cohort. DOI:10.1016/j.radonc.2023.110065

Olloni A, Brink C, Lorenzen EL, Jeppesen SS, Hoffmann L, Kristiansen C, Knap MM, Møller DS, Nygård L, Persson GF, Thing, RS, Sand HMS, Diederichsen A, Schytte T. Heart and Lung Dose as Predictors of Overall Survival in Patients with Locally Advanced Lung Cancer. A National Multicenter study.  Submitted to Journal og Thoracic Oncology

Schougaard, L. M.V., Friis, R. B. et. al. Exploring the Nurses’ Perspective on Using Remote Electronic Symptom Monitoring in Clinical Decision-Making Among Patients With Metastatic Lung Cancer In press.

Gouliaev A, Rasmussen TR, Malila N, Fjellbirkeland L, Löfling L, Jakobsen E, Dalton SO, Christensen NL. Lung cancer registries in Denmark, Finland, Norway and Sweden: a comparison and proposal for harmonization. Acta Oncol. 2023 Jan;62(1):1-7. doi: 10.1080/0284186X.2023.2172687. Epub 2023 Jan 30. PMID: 36718556.

Langballe R, Jakobsen E, Iachina M, Karlsen RV, Ehlers, JH, Svendsen MN, Bodtger U, Hilberg, O, Dalton SO, Bidstrup PE. Who are the vulnerable lung cancer patients at risk for not receiving first-line curative or palliative treatment? Acta Oncologica, 2023 Sep 1:1-8

Langballe R, Svendsen L, Jakobsen E, Dalton SO, Karlsen RV, Iachina M, et al. Addressing disparities in lung cancer survival: feasibility of the NAVIGATE intervention targeting vulnerable patients at risk of non-adherence to treatment Scientific Reports. Accepted for publication Dec 2023.

Rasmussen M.B; Drljevid-Nielsen A; Thygesen J; Kruis M F; Hjorthaug K; Rasmussen F; Nijkamp J. Assesment of Correlation between Dual-Energy Ct (De-Ct)-Derived lodine Concentration and Local Flourodeoxyglucose (Fdg) Uptake in Patients with Primaty Non-Small-Cell Lung Cancer. MDPI, vol 8,

Review: Wen, S.W.C.; Wen, J.; Hansen, T.F.; Jakobsen, A.; Hilberg, O. Cell Free Methylated Tumor DNA in Bronchial Lavage as an Additional Tool for Diagnosing Lung Cancer—A Systematic ReviewCancers 202214, 2254. cancers14092254

Juul A. D. · Falster C. · Rasmussen T.R. · Hilberg O. · Jacobsen N. · Arshad A. · Laursen C.B. Does the Addition of Radial Endobronchial Ultrasound Improve the Diagnostic Yield of Electromagnetic Navigation Bronchoscopy? A Systematic Review – Abstract – Respiration 2022, Vol. 101, No. 9 – Karger Publishers

Circulating tumor DNA monitoring reveals molecular progression before radiologic progression in a real-life cohort of advanced Non-Small Cell Lung Cancer patients. Frank M.S., Andersen C.S.A., Ahlborn L.B., Pallisgaard N., Bodtger U., Gehl J. Cancer Research Communications. Sept 2022.

Actionable Molecular Alterations Are Revealed in Majority of Advanced Non-Small Cell Lung Cancer Patients by Genomic Tumor Profiling at Progression after First Line Treatment Frank, M.S., Bodtger, U., Gehl, J., Ahlborn, L.B. Cancers 2022, 14, 132.

Langballe R, Dalton SO, Jakobsen E, Karlsen RV, Iachina M, Freund KM, Leclair A, Nielsen AS, Andersen EW, Rosthøj S, Jørgensen LB, Skou ST, Bidstrup PE. NAVIGATE – Improving survival in vulnerable lung cancer patients through nurse navigation, symptom monitoring and exercise: study protocol for a multicenter randomized controlled trial. BMJ Open, 2022 Oct 31; 12(10)

Natural killer cell activity as a biomarker for the diagnosis of lung cancer in high-risk patients, Journal of International Medical Research, 2022.

Assessment of circulating biomarkers for detection of lung cancer in a high-risk cohort, Cancer Biomarkers, 2022.

Potential impact of texture analysis in contrast enhanced CT in non-small cell lung cancer as a marker of survival: A retrospective feasibility study

Frank M, Bødtger U et. al: Re-biopsy after first line treatment in advances NSCLC can reveal changes in PD-L1 expression Lung Cancer, Volume 149: 23-32.


Malene Støchkel Frank, Uffe Bodtger, Julie Gehl and Lise Barlebo Ahlborn: Actionable Molecular Alterations are Revealed in Majority of Advanced NOn-Small Cell Lunge Cancer Patients by Genomic Tumor Profiling at Progression after First Line Treatment

Validating Methylated HOXA9 in Bronchial Lavage as a Diagnostic Tool in Patients Suspected of Lung Cancer, Cancers, 2021.

Performance of the EarlyCDT® Lung test in detection of lung cancer and pulmonary metastases in a high-risk cohort, Lung Cancer, 2021.

Skougaard K, Østrup O Surveillance with PET/CT and Liquid Biopsies of Stage I-III Lung Cancer Patients After Completion ofDefinitive Therapy: A Randomized Controlles Trial (SUPER) Clinical Lung Cancer, 2020-0301 Volume 21, Issue 2: e61-e64.

Bødtger U, Høegholm A, Stamp IM, Gehl J Re-biopsy after first line treatment in advanced NSCLC can reveal changes in PD-L1 expression Frank MS, . Lung Cancer. Volume 149. 2020. P 23-32.

Friis, R. b et all Electronic symptom monitoring in patients with metastatic lung cancer: a feasibility study, 2020 Jun 17;10(6):e035673. doi: 10.1136/bmjopen-2019-035673.